Research programme: influenza virus vaccines - LigoCyte

Drug Profile

Research programme: influenza virus vaccines - LigoCyte

Latest Information Update: 14 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LigoCyte Pharmaceuticals
  • Developer Takeda
  • Class Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 14 Feb 2017 Discontinued - Preclinical for Influenza virus infections (Prevention) in USA (unspecified route)
  • 05 Oct 2012 LigoCyte Pharmaceuticals has been acquired and merged into Takeda
  • 18 Mar 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top